Lyra Therapeutics (LYRA) Net Margin (2021 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Net Margin of 12428.57% in Q4 2025, up 48.08% on a QoQ basis from 23936.0% in Q3 2025, and down 1657881.0% YoY from N/an in Q4 2024.
Lyra Therapeutics (LYRA) Net Margin (2021 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Net Margin for 5 consecutive years, with 12428.57% the latest figure, recorded in Q4 2025.
- Net Margin for Q4 2025 came in at 12428.57%, down 1657881.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 5738.19% (down 92841.0% YoY), and the FY2025 annual result was 5738.19%, down 92841.0% from the prior year.
- Net Margin for Q4 2025 stood at 12428.57%, up from 23936.0% in the prior quarter.
- The five-year high for Net Margin was 4150.24% in Q4 2024, with the low at 129290.91% in Q4 2022.
- A 5-year average of 18298.27% and a median of 4445.4% in 2024 frame the typical range for Net Margin.
- Across the five-year window, Net Margin slumped 12423925 bps in 2022 and jumped 11891009 bps in 2023, its largest moves.
- Lyra Therapeutics' Net Margin stood at 5051.66% in 2021, then sank by 2459 bps to 129290.91% in 2022, then surged by 92 bps to 10380.82% in 2023, then soared by 140 bps to 4150.24% in 2024, then slumped by 399 bps to 12428.57% in 2025.
- The last three Net Margin figures came in at 12428.57% (Q4 2025), 23936.0% (Q3 2025), and 4063.93% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -539.31% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.90% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 12.74% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.51% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -3.12% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - | -12,428.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12,428.57% |
| Sep 30, 2025 | -23,936.00% |
| Jun 30, 2025 | -4,063.93% |
| Mar 31, 2025 | -4,670.49% |
| Dec 31, 2024 | 4,150.24% |
| Sep 30, 2024 | -6,088.72% |
| Jun 30, 2024 | -8,048.66% |
| Mar 31, 2024 | -4,220.30% |
| Dec 31, 2023 | -10,380.82% |
| Sep 30, 2023 | -2,877.02% |
| Jun 30, 2023 | -3,410.04% |
| Mar 31, 2023 | -3,964.63% |
| Dec 31, 2022 | -129,290.91% |
| Sep 30, 2022 | -4,113.09% |
| Jun 30, 2022 | -2,736.38% |
| Mar 31, 2022 | -2,545.09% |
| Dec 31, 2021 | -5,051.66% |
| Sep 30, 2021 | -105,692.86% |